Title (en)

METHODS OF TREATING ANTIBODY-MEDIATED REJECTION IN ORGAN TRANSPLANT PATIENTS WITH C1-ESTERASE INHIBITOR

Title (de)

VERFAHREN ZUR BEHANDLUNG VON ANTIKÖRPER-VERMITTELTER ABSTOSSUNG BEI ORGANTRANSPLANTATPATIENTEN MIT C1-ESTERASE-INHIBITOR

Title (fr)

PROCÉDÉS DE TRAITEMENT DE REJET MÉDIÉ PAR LES ANTICORPS CHEZ DES PATIENTS AYANT SUBI UNE GREFFE D'ORGANES À L'AIDE D'UN INHIBITEUR DE C1-ESTÉRASE

Publication

EP 3494988 A1 20190612 (EN)

Application

EP 18205998 A 20141121

Priority

- US 201361907550 P 20131122
- US 201462029086 P 20140725
- EP 14809567 A 20141121
- US 2014066784 W 20141121

Abstract (en)

A method and composition for treating or preventing antibody- mediated rejection (AMR) of a transplanted organ are provided.

IPC 8 full level

A61K 38/55 (2006.01); **A61K 35/16** (2015.01); **A61K 39/395** (2006.01); **A61P 37/00** (2006.01)

CPC (source: EP KR US)

A61K 31/69 (2013.01 - KR); **A61K 35/16** (2013.01 - EP KR US); **A61K 38/55** (2013.01 - EP KR US); **A61K 38/57** (2013.01 - EP KR US); **A61K 39/395** (2013.01 - KR); **A61K 45/06** (2013.01 - KR US); **A61P 1/00** (2018.01 - EP); **A61P 1/04** (2018.01 - EP); **A61P 1/16** (2018.01 - EP); **A61P 1/18** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 11/00** (2018.01 - EP); **A61P 13/12** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 16/00** (2013.01 - EP US); A61K 2035/122 (2013.01 - KR US); A61K 2039/505 (2013.01 - EP KR US); A61K 2300/00 (2013.01 - KR)

C-Set (source: EP US)

A61K 35/16 + **A61K 2300/00**

Citation (applicant)

- "Remington: The Science and Practice of Pharmacy", 2000, LIPPENCOT, WILLIAMS & WILKINS
- A.R. GENARO ET AL.: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS, article "Pharmaceutical Manufacturing", pages: 669 - 1015

Citation (search report)

- [Y] WO 2013041677 A1 20130328 - CSL BEHRING GMBH [DE], et al
- [Y] EP 1240904 A2 20020918 - AVENTIS BEHRING GMBH [DE]
- [AP] WO 2014145519 A2 20140918 - VIROPHARMA HOLDINGS LTD
- [Y] ANONYMOUS: "A Randomized Double-Blind Placebo-Controlled Pilot Study to Evaluate the Safety and Effect of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-Mediated Rejection in Recipients of Donor-Sensitized Kidney Transplants", 18 November 2013 (2013-11-18), XP002734260, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01147302/2013_11_18> [retrieved on 20150108]
- [YP] MONTGOMERY ET AL.: "Human Plasma-Derived C1 Esterase Inhibitor for the Treatment ofAcute Antibody Mediated Rejection in Kidney Transplantation", AMERICAN JOURNAL OF TRANSPLANTATION, vol. 14, no. S3, 2252, 27 June 2014 (2014-06-27), pages 129 - 130, XP002734261
- [Y] CHRISTOPHER R. ENSOR AND CHRISTINA T. DOLIGALSKI: "Antibody Mediated Rejectionof the Cardiac Allograft", 2012, pages 23 - 40, XP002734262, Retrieved from the Internet <URL:http://cdn.intechopen.com/pdfs-wm/28047.pdf> [retrieved on 20150108], DOI: 10.5772/26456
- [Y] ANONYMOUS: "Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection", 10 October 2013 (2013-10-10), XP002734263, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01134510/2013_10_10> [retrieved on 20150108]
- [Y] ERIC WAGNER ET AL: "Therapeutic potential of complement modulation", NATURE REVIEWS DRUG DISCOVERY, vol. 9, no. 1, 1 January 2010 (2010-01-01), pages 43 - 56, XP055085419, ISSN: 1474-1776, DOI: 10.1038/nrd3011
- [Y] ANONYMOUS: "Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation", 15 February 2012 (2012-02-15), XP002734264, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/show/NCT01035593?term=amr+c1&rank=2> [retrieved on 20150108]
- [Y] TILLOU XAVIER ET AL: "Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons.", KIDNEY INTERNATIONAL JUL 2010, vol. 78, no. 2, July 2010 (2010-07-01), pages 152 - 159, XP002734265, ISSN: 1523-1755
- [Y] CAI JUNCHAO ET AL: "Humoral theory of transplantation: some hot topics.", BRITISH MEDICAL BULLETIN 2013, vol. 105, 2013, pages 139 - 155, XP002734266, ISSN: 1471-8391

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2015077543 A1 20150528; AU 2014352846 A1 20160602; AU 2014352846 B2 20191003; AU 2020200015 A1 20200130; CA 2930964 A1 20150528; CN 105744949 A 20160706; CN 111388655 A 20200710; CY 1121298 T1 20200529; DK 3071219 T3 20190225; EP 3071219 A1 20160928; EP 3071219 B1 20181114; EP 3494988 A1 20190612; ES 2708655 T3 20190410; HR P20190184 T1 20190322; HU E041809 T2 20190528; JP 2016537380 A 20161201; JP 2019001831 A 20190110; JP 2019023233 A 20190214; JP 6431912 B2 20181128; JP 6620206 B2 20191211; KR 20160079821 A 20160706; LT 3071219 T 20190110; MX 2016006656 A 20160906; PL 3071219 T3 20190430; PT 3071219 T 20190206; RS 58343 B1 20190329; SG 10201804326S A 20180628; SI 3071219 T1 20190329; US 2015147319 A1 20150528; US 2018104319 A1 20180419; US 9895428 B2 20180220

DOCDB simple family (application)

US 2014066784 W 20141121; AU 2014352846 A 20141121; AU 2020200015 A 20200102; CA 2930964 A 20141121;
CN 201480063697 A 20141121; CN 202010018792 A 20141121; CY 191100119 T 20190129; DK 14809567 T 20141121;
EP 14809567 A 20141121; EP 18205998 A 20141121; ES 14809567 T 20141121; HR P20190184 T 20190129; HU E14809567 A 20141121;
JP 2016532586 A 20141121; JP 2018194167 A 20181015; JP 2018214342 A 20181115; KR 20167013463 A 20141121;
LT 14809567 T 20141121; MX 2016006656 A 20141121; PL 14809567 T 20141121; PT 14809567 T 20141121; RS P20190148 A 20141121;
SG 10201804326S A 20141121; SI 201431066 T 20141121; US 201414550075 A 20141121; US 201715844850 A 20171218